INVEST IN LIFEBRIDGE 10000 TODAY!
Dianna LaTour
Business Strategy Advisor
Scott Hubbard
Global market Strategist/Clinical Research Advisor
Lee M. Zehngebot, MD
Medical Advisor
Avi Roop
Med Device Commercialization
Edward Abt
Accounting
Scott Krywick
Head Programmer
Maximum Number of Shares Offered subject to adjustment for bonus shares
Irregular Use of Proceeds
The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments and salary made to one's self, a friend or relative; Any expense labeled "Administration Expenses" that is not strictly for administrative purposes; Any expense labeled "Travel and Entertainment"; Any expense that is for the purposes of inter-company debt or back payments.
03.29.18
Thank you so much for investing in our mission. We are working hard for you as we believe serving our investors is of equal importance to serving those who need a new cancer therapy. You the investor drive development and the saving of lives. Those of you who are still considering joining our effort by investing, please note the campaign closes at midnight tonight.
Please let me know if you have any questions.
Thank you
Peter
“Because they have more life to live”
Peter F Travers
CEO
LifeBridge 10000, LLC
www.lifebridge10000.com
03.28.18
Thank you so much for investing in our mission. We are working hard for you as we believe serving our investors is of equal importance to serving those who need a new cancer therapy. You the investor drive development and the saving of lives. Those of you who are still considering joining our effort by investing, please note the campaign closes at midnight tonight.
Please let me know if you have any questions.
Thank you
Peter
“Because they have more life to live”
Peter F Travers
CEO
LifeBridge 10000, LLC
www.lifebridge10000.com
03.27.18
https://clinicaltrials.gov/ct2/show/NCT02973789?term=lunar
Above is a picture from NovoCure’ s open phase 3 clinical trail for Non-Small Cell Lung Cancer (NSCLC). We are working hard to develop an advanced form of TTF that is not only more effective, but is designed from the ground up to treat late stage patients with disease in multiple locations, such as the lung and liver simultaneously. One of our main goals is to bring the therapy to these people who would otherwise not benefit.
But, there are hundreds of thousands of patients that can benefit from fixed array TTF. According to the American Cancer Society over 150,000 Americans will die from NSCLC this year, and even larger numbers worldwide. You may be able to help some of them now. If you know of someone with NSCLC please share the link above to NovoCures trial at ClinicalTrials.gov. NSCLC patients working with their doctors can see if they qualify for this important 500-person phase 3 clinical trial. Those that received TTF and followed regimen in the phase 2 trial, fared over a hundred percent better than those on chemo alone.
If you can share this information and someone gets in the NovoCure trail and receives high quality extended life, you will understand the mission of LifeBridge 10000 in a new and personal way.
Peter Travers
CEO
LifeBridge 1000
03.26.18
During our time together on StartEngine your funds have helped us:
You can make a difference. Invest today!
Peter F Travers
CEO
03.25.18
03.23.18
As we speak our engineers are putting our new prototype through its paces. This prototype is larger than fixed array devices being tested on over 500 lung cancer patients in open phase 3 clinical trials.
Our device is built from the ground up to bring tumor treating field therapy to late stage patients with disease in multiple locations like the lung and liver simultaneously. You can help us get to clinical trials by investing today! Thank you on behalf of those who have more life to live! Only days left.
Peter Travers
CEO
LifeBridge 10000, LLC
03.19.18
03.16.18
We have been asked “What if you don’t raise your highest goal on StartEngine?”. LifeBridge began raising funds through a Reg D offering before beginning on StartEngine. Although we are moving our emphasis to title 3 crowdfunding, friends family and accredited investors have continued supporting our research and mission. In January of this year $50,000 came in through our Reg D offering (see below). With your investment and additional commitments, we are approaching a total of $400,000 raised.
Our desire to move to crowd funding is our belief that you are more likely to be missional moving forward. You are OK with making a decent return and giving a percentage of profits to those who cannot afford treatment. We believe our mission will bring us all more profit as we gain the respect of the medical community as a company that cares. The bottom line is our effort will continue with or without crowdfunding. We hope and pray it will be with you, as institutional investors tend to strip away mission.
Please invest today, because they have more life to live!
03.12.18
Link to Mad Money CNBC: https://www.youtube.com/watch?v=0qAlyZhfetc
03.09.18
My wife presented in front of our radiation oncologist with significant back pain from her stage 4 cancer attacking nerves in her lower back. We had run out of chemo’s to use, so radiation was the only known way to keep the pain from becoming debilitating. My wife’s medical chart was still on paper at this point and was literally about 10 inches thick. 18 years and twelve re-occurrences of cancer made for a long history.
The doctor read silently, searching the file when a disappointing look came over his face. He said “about twelve years ago you had a breakout of cancer in your lower back and we used multiple treatments of radiation to resolve the issue. The pain you are experiencing now is in the same area. If we radiate that area again it could damage your nerves and the pain could be much worse. We should only radiate as a last resort”. Out of options is the dreaded destination of the cancer journey, but for us there was good news.
Before we get to the good news, let’s talk for a moment about a lifetime strategy for battling cancer. We learned through my wife’s 18-year battle with stage 4 breast cancer that you are going in to fight with a limited amount of ammunition. Once a certain type of ammunition is used up, you can be left without a defense. Some chemo’s have a lifetime limit to how many doses you can take, because the side effects can put you into a wheel chair or worse. As we learned above, radiating the same area twice is really discouraged, because of the nerve damage and other side effects.
One of the problems with managing cancer is that many times it is managed from 1 re-occurrence to the next without a lifetime strategy. To be fair, that is because there have not been many options for developing a long-term plan. My wife is an example of how Tumor Treating Fields can bring about a new strategy. The day the doctor told us he did not recommend radiating Laurie’s back a second time, he also shared with us the location of the tumors causing the pain. That same day our team began building a new tumor treating field array to cover the area. One for the lower back and one in the front to create the tumor treating field. We called it the bikini array.
Within two weeks of wearing the new array the pain began to subside. Within a month the pain was gone. Tumor treating fields allowed Laurie to avoid a risky treatment. That is the point. Tumor treating fields can be used to create a long-term strategy of preserving various treatments for later use if needed. Here is another example.
Years earlier Laurie had a suspicious tiny spot on her pancreas. To biopsy it would be difficult. The procedure would require going down the throat, out the stomach, capture the sample and back out. Obviously, the doctors wanted to avoid the ordeal. So, we were asked to wait. Almost 3 full months later scans showed that the spot had gotten bigger and the biopsy was ordered. The results showed cancer. One of the most effective chemo’s was used to eliminate the tumor. Not only did Laurie have to lose her hair and go through yet another ordeal, but one our most powerful pieces of ammunition was used up. Years later when Laurie needed it more, it could not be used effectively.
If tumor treating fields were available there is a high probability we would not have had to wait those three months. The tiny tumor could have been eliminated by tumor treating fields and one of the most effective chemo’s could have been saved for later, if needed at all. Not to mention saving Laurie from going through another rough round of side effects. Tumor treating Fields have no side effects to date, only minor skin irritation. Here we are years later and fixed array tumor treating fields for pancreatic cancer is entering a phase 3 clinical trial, after proving to be over a 120% more effective than chemotherapy alone in a phase 2 trial.
Tumor treating fields can potentially change the way long term cancer is managed. Using it against new tumors when they are tiny. Not only does this avoid terrible side effects that strain the patient and whole family, but it preserves lifesaving therapies for later if needed.
You are the key, make a difference today by investing, because they have more life to live!
Thank you for your time, please let me know if you have any questions.
Peter Travers
CEO
LifeBridge 10000, LLC
0/2500
17 INVESTMENTS
5 years ago
2
0
1 INVESTMENTS
5 years ago
1
0
1 INVESTMENTS
5 years ago
1
0
33 INVESTMENTS
5 years ago
1
0
LifeBridge 10000
•
5 years ago
0
0
LifeBridge 10000
•
5 years ago
0
0
LifeBridge 10000
•
5 years ago
0
0
LifeBridge 10000
•
5 years ago
0
0
LifeBridge 10000
•
5 years ago
0
0
Cancel anytime before 48 hours before a rolling close or the offering end date.
We want you to succeed and get the most out of your money by offering rewards and memberships!
Your info is your info. We take pride in keeping it that way!
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
Important Message
IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.
www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.
Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.
Investment opportunities posted and accessible through the site are of three types:
1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.
Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.
By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.
Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.
California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.
StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.
John Young
17 INVESTMENTS
5 years ago
2
0